Prior to this round Secures $15 Million in Latest Seed Funding Round

Prior to this round secured $15 million in its latest Seed, adding another data point to the Healthcare & Life Sciences funding market.

Prior to this round Raises $15 million in Funding

Prior to this round, the company raised $10 million in a seed financing round led exclusively by Qiming Venture Partners. Convergen logo The proceeds will be used to further advance Convergen's proprietary degrader platform and accelerate its pipeline for neurodegenerative disorders and other protein aggregation diseases.

Investors Behind the Funding

The round was backed by MPCi. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Prior to this round operates in Healthcare & Life Sciences. Prior to this round's financing adds to recent private-market activity.

Strategic Use of Funds

Advance Therapeutics for Protein Aggregation Diseases.

Looking Ahead

We are grateful to the distinguished group of investors and their confidence in our science, platform and team,

Source reference: original announcement/article.